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Summary
Until recently gait has been considered as an automated motor activity
independent from cognitive function. However, recent arguments suggest
a strong link between gait and cognition, in particular in neurodegenera-
tive disorders such as Alzheimer’s disease and related disorders. Executive
functions seem to play a central role in these gait disorders due to deficits in
cognition.
The purpose of this article is to discuss the relationship between gait and
cognition and the specific impact of executive function by reviewing the
type of gait disorders observed in some frequent neurodegenerative and non
degenerative disorders mainly affecting cognitive function. The potential
contribution of some rehabilitation techniques and pharmacological treat-
ments in improving gait disorders related to impaired cognitive function is
discussed.
The clinical implications of the relationship between gait and cognition
are that gait assessment should be considered as a part of the routine assess-
ment of cognitive function and conversely, cognitive function and specifi-
cally executive function should be assessed in patients with gait disorders.
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Introduction
Gait has traditionally been considered as a simple auto-
matic motor activity that was independent of cognition.
Spinal neuronal networks that include motoneurons and
interneurons called “central pattern generators” allow the
generation of automatic and rhythmic motor activity
patterns [1]. These spinal networks are under the influence
of basal ganglia and the brainstem nuclei, including the
pedunculopontine nucleus, which play a role in the initia-
tion and modulation of the pattern generators [2]. Basal
ganglia and their connection with cortical regions through
the cortico-subcortical loops play a central role in both
movement initiation and cognitive aspects, such as exe-
cutive functioning. However, evidence also points to a
control of these subcortical structures by cortical regions
[3]. This becomes clear, for example, from the observation
that older adults display a certain modification of their gait.
Some authors considered gait apraxia as a sign of a frontal
dysfunction [4]. Historically, the precise cortical location of
gait apraxia has remained undefined although the greatest
interest has focused on frontal regions including the bilateral
medial areas of the frontal cortex [5]. Changes in this region,
usually considered as a consequence of aging, have recently
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been identified as a risk factor for dementia [6], illustrating
the relationship between gait and cognition.
The influence of cognitive function on gait can be effec-
tively assessed using a dual task paradigm, which requires
the subject to perform a cognitive, attention-demanding
task while walking [7]. The ability to dual-task reflects
the capacity to appropriately allocate attention between
two tasks performed simultaneously, an ability related to
executive function. Interference in this paradigm is defined
as a modification of performance on one or both tasks, as
compared to performance under a single-task condition [8].
Interference of a cognitive task with gait has been demon-
strated in healthy older adults [9], as well as in subjects with
cognitive dysfunction, such as Alzheimer’s disease (AD)
[10], vascular dementia, mixed dementia [8] or Parkinson’s
disease [11]. This interference of the attention-demand-
ing task with walking suggests that both tasks rely on the
same functional subsystem and that gait also requires atten-
tion [7]. This link between gait and attention becomes even
more evident as the secondary task becomes more complex.
For example, in subjects with impaired executive function,
counting backwards while walking results in larger changes
in gait parameters than does walking while counting for-
wards [12]. In fact, what previously described pathologies
with gait modifications and normal aging have in common
is a deficit in executive function. Furthermore, previous
studies have shown that patients with psychoaffective dis-
orders such as anxiety and depression, which also encom-
pass some degree of executive dysfunction, also show spe-
cific gait disorders [13]. These different observations in
healthy subjects and patients with neurodegenerative or
psychoaffective disorders converge to suggest a strong link
between gait and cognition.
Recently, an increasing number of studies have
examined gait in neurodegenerative disorders. This area of
research represents the central core of this article, in which
wewill review the type of gait disturbances in some frequent
neurodegenerative and non degenerative disorders that
principally affect cognition.
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Alzheimer’s disease
In the field of gait, AD is the pathology most studied, and
the most diverse analytical approaches have been used. In
this condition, motor dysfunction is already present in the
earliest stage of the disease, before the presence of clinically
confirmed extrapyramidal dysfunction [14]. A “cautious
gait” has repeatedly been described in mild AD patients [15].
In the O’Keffe study, using the classification of Nutt [16],
the authors showed that subjects with moderate dementia
present with a cautious gait, whereas subjects with a severe
dementia present with a “frontal gait”. Many other clinical
observations have been reported with regard to different
gait parameters in AD, such as a decrease in gait speed, a
decrease in step length and an increase in step width. As
early as 1983, Visser et al. showed that patients with AD pre-
sented with a decrease in gait speed and step length and an
increase in step variability [17]. The authors suggested that
“the findings are consistent with the view that transcortical
pathways participating in the integration of gait are damaged
in senile dementia of the Alzheimer type”. More recently,
these modifications of gait parameters in AD have been
related to a reduced frontal cerebral blood flow, meas-
ured using single photon emission computed tomography
(SPECT) [18]. The presence of motor signs including gait
disorders in AD has been associated with a bad progno-
sis in terms of institutionalisation and mortality [14], and
the presence of gait disorders at the time of diagnosis has
been associated with reduced survival duration [19]. In a
prospective observational study in elderly persons with-
out dementia, it was demonstrated that the presence of gait
abnormalities at baseline was a significant predictor of the
risk to develop of a non-AD dementia [6].
Falls, related to gait instability and irregularity [20],
are one of the consequences of gait disorders as the disease
evolves. In a prospective study assessing falls and gait dis-
orders in subjects with AD, there was a correlation between
step length variability, number of falls and the severity of
dementia [21]. This step length variability reflects an alter-
ation of gait automaticity, which is related to the activity of
associative cortical areas. For example in AD, different types
of apraxia and alteration of executive function may appear
during the course of the disease, causing a deficit in motor
programming. This deficit affects different aspects of gait and
induces a loss of gait automaticity, with as a consequence
increased risk of falling [22].
Dual-task related gait changes have also been studied in
AD. For example, in a cross-sectional study, twenty-eight
AD patients with impaired executive function presented
increased gait variability during dual-task conditions [12].
The authors suggested that this susceptibility to distraction
and its effect on gait variability could explain the higher risk
of falls observed in patient with AD.
Subcortical ischaemic vascular dementia
Subcortical ischaemic vascular dementia (SIVD), a sub-
type of vascular dementia, refers to ischaemic lesions in-
volving basal ganglia, cerebral white matter and brainstem
[23]. Gait disorders are very common in SIVD and a wide
range of gait disturbances has been described in this pa-
thology, including wide-based gait, decreased step length,
bradykinesia, rigidity, disturbance in initiation of gait, static
and dynamic instability, freezing gait and gait apraxia [20].
Walking speed is even slower in SIVD than in AD [24]. Fur-
thermore, a modification of the gait pattern, namely an
increased variability of spatio-temporal gait parameters, has
been shown in presymptomatic patients, and a greater varia-
bility of step length was specifically associated with a greater
burden of cerebral vascular abnormalities [25]. In another
study, white matter lesions have been shown to be associ-
ated with a decreased walking speed and longer double sup-
port time [26]. In the larger field of vascular dementia, some
authors have defined a “high-risk neurological gait” syn-
drome, involving the presence of a hemiparetic, frontal or
unsteady gait. These latter gait disorders are associated with
a high risk of developing vascular dementia and this risk is
increased if patients also present with a dysexecutive syn-
drome [27]. Recently, a French longitudinal study dem-
onstrated that, in a sample of 1086 subjects, the volume of
periventricular white matter lesions correlated with a slower
walking speed at baseline and at follow-up eight years later
[28]. In the same cohort, a cross-sectional association was
Figure 1
A 63-year-old man hospitalized for a 3-year history of isolated
progressive gait apraxia. His EEG showed an isolated slowing in
the prefrontal regions (a) and he presented a focal mediofrontal
atrophy on MRI (b). The progressive gait apraxia was related to
a focal dysfunction of the prefrontal frontal lobe.
a
b
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demonstrated between walking speed and homocysteine,
a marker of the risk of cardiovascular disease, again illus-
trating the role of vascular factors in motor function [29].
In a prospective cohort study with 422 subjects without de-
mentia, the presence of gait abnormalities at baseline was a
significant predictor of the risk of developing a non-Alzhei-
mer’s dementia, in particular vascular dementia [6]. These
findings raise the interesting possibility of considering gait
disorders as possible markers of incipient SIVD.
Frontotemporal lobar degeneration
Frontotemporal lobar degeneration represents a large spec-
trum of pathologies, including those that involve the mo-
tor system. One certain subtype of frontotemporal demen-
tia with parkinsonism has been associated with mutations
in the tau gene linked to chromosome 17 [30]. Another
link between frontotemporal lobar degeneration and motor
dysfunction is illustrated by the relatively high association
(around 5%) of amyotrophic lateral sclerosis and fronto-
temporal dementia. Furthermore, some subtypes of fronto-
temporal lobar degeneration share certain neuropatho-
logical characteristics with corticobasal degeneration and
progressive supranuclear palsy [31], two conditions mainly
affecting motor functions.
Gait disorders are not part of the clinical definition of
the temporal or the frontal form of frontotemporal lobar
degeneration. However, in a recent comparative study with
sixty subjects with the behavioural variant of frontotempo-
ral lobar degeneration (bvFTD), AD patients and healthy
control subjects, we showed an increased gait instability
– defined as stride time variability – in the bvFTD group,
both during walking alone and during dual tasking such as
walking while counting backwards [32]. Given the specific
pattern of bilateral atrophy of the frontal and anterior tem-
poral lobes in bvFTD, this study emphasised the role of these
regions in gait control. Beside gait disorders, bvFTD patients
also displayed more stereotypical movements and compul-
sive-like behaviours than AD patients [33]. Interestingly,
these stereotypical movements decreased when a serotonin-
selective inhibitor was administered.
Dementia with Lewy bodies and Parkinson’s disease
with dementia
Apart from being associated with a different age of onset,
temporal course and levodopa-responsiveness, dementia
with Lewy bodies (DLB) and Parkinson’s disease with de-
mentia (PDD) are two very similar conditions [34]. Both
motor features and neuropsychiatric symptoms in both
pathologies are most likely caused by the neurodegenera-
tion within the cholinergic system and Lewy body accumu-
lation in the cortex [35].
Few studies have investigated gait parameters in DLB
and PDD in detail. Gait disorders appear to be more com-
mon in PDD and DLB than in Parkinson’s disease [35]. In a
two-year follow-up study, it was demonstrated that postural
instability and gait disorders in Parkinson’s disease were
associated with a faster rate of cognitive decline and could
be considered as risk factors for developing PDD [36]. In a
comparative study assessing quantitative gait parameters in
DLB and AD subjects, it was demonstrated that there were
no differences between both pathologies in terms of any of
the measured gait variables. An explanation for this surpris-
ing result may be that only a simple gait task (walking in
a straight line), not involving phases of acceleration and
deceleration was used [37].
Normal pressure hydrocephalus
The diagnosis of normal pressure hydrocephalus (NPH) is
suggested when the clinical triad of gait disorder, cognitive
dysfunction and urinary incontinence is combined with a
magnetic resonance image showing a disproportionate ven-
tricular enlargement and aqueductal signal loss [38]. Gait
deficits usually appear first and are characterised by a re-
duced speed and stride length, a reduced step height during
the swing phase and a wide-based gait with a relatively
preserved arm swing [39]. One hypothetical reason for this
early gait involvement in the disease is that the fibres of
the corticospinal tract responsible for motor function in the
legs run close to the lateral ventricles in the corona radiata
[40]. In a study comparing gait patterns in NPH and Parkin-
son’s disease, wide-based gait and a diminished step height
during the swing phase were the features specific to NPH
[41]. After cerebrospinal fluid tapping, only gait velocity and
stride length were abnormal in the NPH group in the same
study [41]. These results confirmed those of a previous study
showing that spinal tapping only improved stride length
in NPH patients [39]. In a recent cross-sectional study with
858 subjects, in which the correlation between ventricular
volume and gait impairment, cognitive disorders and urinary
incontinence was assessed, the prevalence and severity of
gait and cognitive impairment increased with ventricular
dilation, independent of bladder dysfunction [42].
Treatment
While many studies have now established the relationship
between gait disorders and cognition in neurodegenerative
diseases, few studies have investigated treatment of these
gait disturbances. Possibilities for treatment are rehabilita-
tion techniques, such as those used in Parkinson’s disease,
or pharmacological therapies.
A recent review looked at the positive effects of tread-
mill walking in the treatment of gait disturbance [43]. The
putative mechanism of this therapy is that it stimulates neu-
ronal circuits which include central pattern generators. The
effect of treadmill training has also been assessed in others
pathologies, such as stroke and spinal cord injury. In Parkin-
son’s disease, another treatment strategy that has been eval-
uated is that of cueing. Auditory, visual, tactile and cognitive
cues from the environment or generated by the patient are
thought to facilitate automatic movements. The hypothesis
is that cues provide an external rhythm that can compen-
sate for the deficient internal rhythm of the basal ganglia in
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Parkinson’s disease. Investigating the effects of regular long-
term practice of a multi-tasking activity, we have demon-
strated that elderly subjects displayed a more stable gait than
age-matched healthy control subjects who did not engage
in any particular routine exercise [44]. Likewise, a recent
study showed positive effects of Tango lessons on mobility
in patients with Parkinson’s disease [45].
With respect to pharmacological treatment, a promis-
ing therapeutic approach is to modulate the norepinephrine
system with an amphetamine-like psychomotor stimulant,
such as methylphenidate. A first report in twenty-one
patients with Parkinson’s disease demonstrated a benefit
of methylphenidate on gait two hours after the adminis-
tration of a single dose [46]. These positive results were
confirmed in another cohort of patients with Parkinson’s
disease [47]. In a study with older adults without dementia,
it was demonstrated that methylphenidate improves certain
aspects of gait stability, suggesting an interesting remedy
for reducing fall risk in older adults [48]. The effect of the
NMDA antagonist amantadine on gait was assessed in forty
patients with subcortical vascular encephalopathy, in an
attempt to reduce the overactive glutamatergic transmission
in this population. Encouraging results have been reported
for the amantadine group with respect to certain gait para-
meters [49]. The effect of this molecule was also evaluated
in some case reports of patients with Parkinson’s disease and
freezing of gait [50]. Several other molecules, such as anti-
depressive drugs, methylphenidate and acetylcholinesterase
inhibitors, have been evaluated in small groups of patients
with freezing of gait [50].
Given that dual-task related gait changes in patients
with dementia are strongly related to impaired executive
function [3] and acetylcholinesterase inhibitors are known
to improve executive function in AD [51], we recently
tested the effect of acetylcholinesterase inhibitors on gait
in patients with AD. In a small sample of nine AD subjects,
we demonstrated an improvement of dual-task related gait
performance after 24 weeks of galantamine treatment [52].
In general, however, the potential benefits of pharmacolo-
gical treatment on gait disorders related to impaired cogni-
tive function have only been studied in few and small-scale
studies. There is thus a great need for prospective studies to
investigate the working of these substances and their precise
effect on the different types of gait disturbances.
Conclusion
In this review on the relationship between gait and cogni-
tion and the impact of executive function, we have high-
lighted the frequent co-occurrence of disturbances of motor
and cognitive functions in the most prevalent subtypes of
dementia. Several converging sources of research support
the theory that cognitive-related gait changes are not only
a direct result of motor disorders with a subcortical origin,
but are also associated with the processing of information in
cortical regions. Executive dysfunctions appear to contribute
strongly to these gait modifications with a cortical origin
(fig. 2). One important clinical implication of the reviewed
findings is that gait assessment should become part of the
routine screening of cognitive function and, conversely,
cognitive function (above all executive function) should be
carefully followed up in patients with gait disorders. More-
over, certain methods of gait assessment, such as walk-
ing while performing a cognitive task, may be useful in
the early diagnosis of dementia. Finally, there are some
promising therapeutic options that could be advantageous
for patients, not only to improve cognitive aspects of their
disease, but also their specific gait disturbances.
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